Study guide
Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols
AANPCB Adult-Gerontology Primary Care Nurse Practitioner A-GNP
Track your progress as you read
Finished sections get a check mark.
1 Exam Structure, APRN Foundations & Geriatric Assessment
A-GNP Exam Logistics, Blueprint & Scoring Structure APRN Scope of Practice, Consensus Model & Interprofessional Collaboration Comprehensive Health History & Subjective Assessment Across Adult Lifespan Comprehensive Physical Examination & Clinical Assessment Skills
2 Health Assessment, Diagnostic Reasoning & Clinical Procedures
Diagnostic Reasoning, Test Interpretation & Clinical Decision-Making Screening Guidelines & Evidence-Based Health Promotion (USPSTF) Comprehensive Geriatric Assessment (CGA), Frailty & Function In-Office Clinical Procedures, ECG Interpretation & Minor Surgical Skills
3 Cardiovascular & Peripheral Vascular Disorders
Essential Hypertension & Hypertensive Urgency/Emergency Management Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
4 Respiratory, HEENT & Dermatological Disorders
Asthma Management across the Adult Lifespan (GINA Guidelines) Chronic Obstructive Pulmonary Disease (COPD) Staging & Management (GOLD Guidelines) Community-Acquired Pneumonia & Lower Respiratory Tract Infections Common HEENT Disorders: Otitis, Sinusitis, Pharyngitis, Glaucoma & Macular Degeneration
5 Endocrine, Metabolic & Renal/Genitourinary Disorders
Type 2 Diabetes Mellitus Management Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Subclinical Disease Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy Genitourinary Disorders: BPH, Urinary Incontinence, UTIs & Prostatitis
6 Gastrointestinal, Hematologic & Immunologic Disorders
Upper Gastrointestinal Disorders: Dyspepsia, GERD, PUD & H. pylori Lower Gastrointestinal Disorders: IBS, IBD, Diverticulitis & Colorectal Screening Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis Hematologic & Immunologic Disorders: Anemias, Anticoagulation & Immunizations
7 Neurological, Cognitive & Psychiatric Disorders
Cognitive Assessment: Delirium, Dementia & Mild Cognitive Impairment Neurological Disorders: Stroke, TIA, Parkinson's Disease & Headache Syndromes Major Depressive Disorder & Anxiety Disorders in Adults & Older Adults Sleep Disorders, Insomnia & Restless Legs Syndrome
8 Geriatric Syndromes, Polypharmacy & Deprescribing
The Beers Criteria & STOPP/START Criteria for Potentially Inappropriate Medication Use Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols Fall Risk Assessment (CDC STEADI), Gait/Balance & Mobility Impairments Pressure Injury Prevention/Staging, Urinary/Fecal Incontinence & Frailty Assessment
9 APRN Professional Practice, Ethics, Quality & Healthcare Policy
Musculoskeletal Disorders: Osteoarthritis, Osteoporosis, Gout & Back Pain Dermatological Disorders: Lesions, Skin Cancers, Infections & Rash Evaluation Palliative Care, Advance Care Planning, Pain Management & End-of-Life APRN Professional Practice, Quality Improvement, Ethics & Healthcare Policy
Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols
Key Takeaways Explain This Topic AI
Polypharmacy is defined as the concurrent routine use of 5 or more medications, whereas hyperpolypharmacy involves 10 or more medications, exponentially increasing adverse drug events and functional decline.
Age-related pharmacokinetic changes include increased body fat (expanding volume of distribution for lipophilic drugs), decreased total body water (higher serum concentrations for hydrophilic drugs), decreased plasma albumin, and reduced hepatic Phase I metabolism and renal eGFR clearance.
A prescribing cascade occurs when an unrecognized adverse drug reaction is misdiagnosed as a new clinical condition, resulting in an unnecessary secondary drug prescription.
Systematic deprescribing follows a 5-step protocol: comprehensive medication review, identifying PIMs, assessing discontinuation feasibility, formulating a personalized tapering schedule, and close outcome monitoring.
Last updated: July 2026
- Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols
- Polypharmacy and Hyperpolypharmacy
Managing multimorbidity in older adults frequently leads to complex medication regimens. Polypharmacy is clinically defined as the routine, concurrent use of five or more medications (including prescription drugs, over-the-counter [OTC] medications, dietary supplements, and herbal products). Hyperpolypharmacy is defined as the concurrent use of ten or more medications .
Polypharmacy is an independent risk factor for adverse drug reactions (ADRs), harmful drug-drug interactions, non-adherence, medication errors, cognitive impairment, functional decline, fall-related fractures, acute hospitalizations, and all-cause mortality. As the number of concurrent medications increases, the probability of an adverse drug interaction approaches 100% when a patient takes eight or more drugs.
The Prescribing Cascade Phenomenon
A major driver of polypharmacy is the prescribing cascade . A prescribing cascade occurs when an adverse drug reaction caused by one medication is misdiagnosed as a new, independent medical condition, prompting the clinician to prescribe a second medication to treat the drug-induced symptom. The second drug often produces additional side effects, triggering further prescriptions.
Classic Clinical Examples of Prescribing Cascades:
Dihydropyridine CCB Cascade: An NP prescribes amlodipine for hypertension. The patient develops bilateral lower-extremity peripheral edema. The clinician misinterprets the edema as worsening heart failure and prescribes furosemide . The diuretic subsequently causes hypokalemia, hyperuricemia, or orthostatic hypotension.
Cholinesterase Inhibitor Cascade: A patient with Alzheimer's dementia is started on donepezil . Donepezil causes bladder detrusor hyperactivity and urinary urge incontinence. The provider prescribes oxybutynin (an anticholinergic). Oxybutynin crosses the blood-brain barrier and antagonizes donepezil, causing rapid cognitive deterioration and delirium.
NSAID Cascade: A patient takes chronic oral ibuprofen for knee osteoarthritis. The NSAID induces fluid retention and elevates blood pressure. The clinician misdiagnoses essential hypertension and adds an antihypertensive agent (e.g., lisinopril).
Dopamine Antagonist Cascade: A patient prescribed haloperidol or metoclopramide develops drug-induced parkinsonism. The provider misdiagnoses Parkinson's disease and initiates levodopa/carbidopa .
Age-Related Pharmacokinetics (PK) Changes
Pharmacokinetics describes what the body does to a drug (Absorption, Distribution, Metabolism, and Excretion [ADME]). Normal physiological aging significantly alters each PK phase.
1. Absorption
Physiological Changes: Decreased gastric acid secretion (elevated gastric pH), reduced mucosal surface area, delayed gastric emptying, and decreased splanchnic blood flow.
Clinical Impact: Passive absorption of most oral drugs remains intact, but drugs requiring an acidic environment (e.g., iron salts, calcium carbonate) exhibit decreased bio-availability.
2. Distribution
Physiological Changes: Relative increase in total body fat (mass increases by 20–40%), decrease in total body water (water decreases by 10–15%), and reduction in serum plasma albumin.
Fat-Soluble Drugs: Lipophilic medications (e.g., diazepam , amiodarone) have an increased volume of distribution ( V d V_d V d ). These drugs accumulate in adipose tissue, significantly prolonging elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) and causing protracted sedation.
Water-Soluble Drugs: Hydrophilic medications (e.g., lithium , digoxin , gentamicin) have a decreased volume of distribution ( V d V_d V d ), leading to higher peak serum concentrations and acute toxicity.
Protein Binding: Highly protein-bound drugs (e.g., warfarin , phenytoin ) have less bound drug and a higher proportion of active "free" drug in circulation when serum albumin is low (<3.5 g/dL).
3. Metabolism
Physiological Changes: Hepatic mass decreases by 20–30%, and hepatic blood flow declines by 20–40%.
Phase I vs. Phase II Metabolism: Phase I reactions (CYP450 oxidation, reduction) decline significantly, prolonging half-lives of drugs like diazepam and warfarin. Phase II reactions (glucuronidation, conjugation) are preserved in healthy aging. Benzodiazepines cleared via direct Phase II glucuronidation—recalled by the mnemonic LOT ( L orazepam, O xazepam, T emazepam)—are preferred in geriatrics.
4. Excretion
Physiological Changes: Progressive reduction in renal mass, renal blood flow, and GFR (eGFR declines ~1 mL/min/year after age 40).
Serum Creatinine Pitfall: Serum creatinine alone is an unreliable indicator of renal function in older adults due to age-related loss of muscle mass (sarcopenia). Clinicians must calculate Cockcroft-Gault CrCl or CKD-EPI eGFR to adjust renally cleared drugs (gabapentin, DOACs, digoxin).
Age-Related Pharmacodynamics (PD) Changes
Pharmacodynamics describes what the drug does to the body. Older adults demonstrate altered end-organ sensitivity and reduced homeostatic compensatory mechanisms.
CNS Sensitivity: Increased blood-brain barrier permeability and altered receptor density increase CNS sensitivity. Opioids, benzodiazepines, and anticholinergics produce exaggerated sedation, ataxia, and delirium at lower doses.
Cardiovascular Sensitivity: Blunted baroreceptor reflex responsiveness impairs compensation for postural changes. Vasodilators, alpha-blockers, and diuretics produce severe orthostatic hypotension .
The 5-Step Evidence-Based Deprescribing Protocol
Deprescribing is the systematic, supervised process of dose reduction or discontinuation of medications that may cause harm, lack clinical efficacy, or no longer align with patient goals.
Step-by-Step Execution:
Step 1: Comprehensive Reconciliation: Obtain a complete list of all active medications, including OTCs, herbals, topicals, and eye drops ("brown bag" review).
Step 2: Identify PIMs and Prescribing Cascades: Cross-reference active drugs against Beers, STOPP, and ACB scales. Identify unindicated drugs or prescribing cascades.
Step 3: Assess Feasibility and Prioritize Targets: Determine which drugs pose the highest risk of acute harm. Engage in shared decision-making with the patient and caregivers to align therapy with goals of care.
Step 4: Formulate Individualized Tapering Protocols: Gradually taper drugs associated with withdrawal syndromes:
Proton Pump Inhibitors (PPIs): Taper over 4 to 8 weeks (reduce dose by 50% every 2 weeks, then switch to every-other-day dosing) to prevent rebound acid hypersecretion .
Beta-Blockers: Taper slowly over several weeks to avoid rebound tachycardia, chest pain, and hypertension.
Benzodiazepines & Gabapentinoids: Reduce daily dose by 10% to 25% every 1 to 2 weeks over several months to prevent withdrawal seizures, severe anxiety, and delirium.
Step 5: Close Monitoring and Patient Communication: Follow up frequently to evaluate for withdrawal symptoms, disease recurrence, or clinical improvement. Frame deprescribing positively as a proactive measure to optimize vitality and prevent drug-induced illness.